Official Title
The Outcome of Dexamethasone and Methylprednisolone Treatment for Patients With ARDS Caused by COVID-19
Brief Summary

A randomized clinical trial designed and intended to evaluate the efficacy of Dexamethasone and Methylprednisolone as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by coronavirus disease 19 (COVID-19). Our aim is to find the best option for the treatment and management of ARDS in COVID-19 patients.

Unknown status
COVID19
ARDS

Drug: Dexamethasone

Injectable solution

Drug: Methylprednisolone

Injectable solution

Eligibility Criteria

Inclusion Criteria:

• Moderate to severe COVID-19 requires hospitalization. SARS-CoV-2 infection will be
confirmed by RT PCR / CT Chest in every case.

Exclusion Criteria:

- Participants with uncontrolled clinical status who were hospitalized from the before.

- Contraindication / possible drug interaction.

- Participants who have any severe and/or uncontrolled medical conditions like, Severe
ischemic heart disease, epilepsy, malignancy, Pulmonary/renal/hepatic disease,
pregnancy, Corpulmonale, etc.

Eligibility Gender
All
Eligibility Age
Minimum: 20 Years ~ Maximum: 80 Years
Countries
Bangladesh
Locations

Chattogram General Hospital
Chittagong, Bangladesh

M. Abdur Rahim Medical College Hospital
Dinajpur, Bangladesh

Contacts

Abu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD
008801817711079
dr_mohiuddinchy@yahoo.com

Shubhashis Talukder, MBBS, DO
008801911882232
drshubhashis@gmail.com

Health Science Center of Xi'an Jiaotong University
NCT Number
Keywords
COVID 19
dexamethasone
Methylprednisolone
ARDS
MeSH Terms
COVID-19
Dexamethasone
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate